An op-ed at the New York Times points out that precision medicine's failures should also be discussed.
The CPMC study aims to provide participants with their genetic and non-genetic risks for disease and drug response and monitor how their behaviors change.
The study is testing the efficacy of cancer treatments that are selected based on genomic markers driving patients' tumors, regardless of cancer type.
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Indian DTC genomics company Mapmygenome has enlisted Israel-based Digital DNAtix to move its interpretation and personalized medicine services to a blockchain.
Early trial results seem promising for Alzheimer's disease treatments, the Los Angeles Times reports.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
While the '3G' study did not establish clinical utility, the researchers said it shows genomic profiling to guide gastric cancer treatment is feasible.
Wired looks into Moderna Therapeutics' work on personalized cancer vaccines.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.